For years, the shingles vaccine has been recommended to prevent the painful rash caused by the reactivation of the varicella-zoster virus​ – the same virus that causes chickenpox. But groundbreaking research ⁣presented at IDWeek 2025 reveals a surprising and important benefit: vaccination against shingles is ⁢linked to⁣ a substantially lower risk of serious⁤ cardiovascular and neurological events in ‌adults age ⁢50 and​ older.

A comprehensive study analyzing the ‍health records of over 174,000 adults across 107 U.S. health systems demonstrated a compelling correlation. Participants who received the shingles vaccine, and were followed for a period ranging from three months to seven years, experienced a 21% reduction in overall mortality risk compared to those who‍ hadn’t‍ been vaccinated. The benefits extended beyond survival rates.

Researchers found that vaccinated individuals had⁢ a 25% lower risk of⁣ experiencing a‌ heart​ attack or stroke, and a ‍27% lower risk of developing blood clots. perhaps most‍ strikingly, the shingles vaccine was associated ⁢with a 50% reduction in the risk of vascular dementia – a form of ‌cognitive decline caused by reduced​ blood ​flow to the brain.

“These findings underscore that shingles is more than just a rash,” explains a leading researcher involved in the study. “The inflammation associated with shingles‍ can trigger complications affecting both the heart and the ⁢brain.Our research suggests the vaccine may ‌offer a protective ‍effect against these serious⁤ consequences, ‍especially for individuals already vulnerable to cardiovascular⁣ disease.”